LILAK · Liberty Latin America Ltd.

Current Thesis

Liberty Latin America's cash-flow recovery and repurchases underpin the rerating case; Q3 execution and a weekly close above the September 18 high-water mark of $8.85 would confirm it, while a weekly close below $6.60 would invalidate it. The operating evidence remains the August 5 Q2 release and August 6 call: adjusted operating income before depreciation and amortization (OIBDA) reached $436 million, with a 40% margin, and management described accelerated repurchases into Q3. Q2 results

The September 18 adjusted reference close was $8.40, against $8.45 on September 4. The current snapshot shows a three-month gain of 58.5%, but a 14-day relative strength index (RSI) of 47.4. As an inference, the narrative is maturing — UBS's September 3 Neutral initiation broadened coverage, while the September 18 close remained below the earlier September 4 close. Those observations do not establish the mainstream participation needed to sustain the prior saturation claim. UBS action

Bullish and bearish views on Liberty Latin America Ltd.

The model's bull view on Liberty Latin America Ltd. (LILAK), in brief: Operating margins have improved. The August 5 Q2 release reported revenue of $1.103 billion and adjusted OIBDA growth of 3% on the company's rebased measure, with a 40% margin. This supports an operating-recovery thesis even before a structural transaction. Q2 results… The bear view: Debt limits financial flexibility. The August 6 Q2 call reported $8.5 billion of debt, $700 million of cash and consolidated net leverage of 4.6 times. A Q3 increase in leverage alongside weaker operating earnings would contradict the financial-recovery case. Cash generation… Both cases follow in full.

Bull Case

• Operating margins have improved. The August 5 Q2 release reported revenue of $1.103 billion and adjusted OIBDA growth of 3% on the company's rebased measure, with a 40% margin. This supports an operating-recovery thesis even before a structural transaction. Q2 results
• Repurchases provide a measurable test. Management reported more than $60 million repurchased during 2026 through the August 6 call, with $140 million of authorization remaining. The next results must establish whether the stated Q3 acceleration occurred; authorization alone is not execution. Q2 materials
• Cost reductions have a timetable. The August 5 Amdocs announcement described a 10-year engagement with company-estimated net present value above $250 million and transition starting in Q4 2026. That figure is a management estimate, not realized savings; a disclosed postponement would undermine this supporting leg. Company announcement

Bear Case

• Debt limits financial flexibility. The August 6 Q2 call reported $8.5 billion of debt, $700 million of cash and consolidated net leverage of 4.6 times. A Q3 increase in leverage alongside weaker operating earnings would contradict the financial-recovery case.
• Cash generation remains uneven. The August 6 call reported adjusted free cash flow before distributions of $83 million for Q2 but $19 million for the first half of 2026. The first-half figure does not establish recurring coverage of repurchases and preferred distributions.
• Analyst support remains qualified. Citi's August 13 action and UBS's September 3 initiation each paired a $9.00 target with a Neutral rating. Their targets are attributed forecasts, not evidence of incremental demand. Dated analyst actions

Setup & Price Structure

The September 18 adjusted close of $8.40 was 5.1% below the supplied 52-week high of $8.85. The positive three-month price change and RSI of 47.4 describe a substantial preceding advance with weaker recent momentum. The current evidence contains no moving-average level, so distance above a rising average cannot be stated.

The published $6.60 weekly-close boundary remains the thesis invalidation threshold; it is a research condition, not newly verified chart support. A weekly close above $8.85 would establish price confirmation beyond the high recorded in the September 18 snapshot. Confirmation of the full case also requires Q3 repurchase execution and an adjusted OIBDA margin at least matching Q2's 40%.

Crowding is unmeasured. The September 3 UBS initiation is an observable expansion in coverage, but neither that event nor the dated analyst ratings establish retail concentration, short exposure or institutional flows. The sample is too small to support a crowding claim.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Q3 reporting period ends. The August 6 call identified Q3 as a period of accelerated repurchases. Quarter-end fixes the measurement period; it is not a scheduled disclosure of the result.
• 2026-10-01 — Q4 transition window opens. The August 5 Amdocs announcement specified a Q4 2026 start. October 1 is the calendar opening of that window, not a confirmed implementation date. Amdocs announcement
• ~2026-11-04, est. Q3 results. This remains an unconfirmed reporting estimate. The release is the later event on which the thesis turns: it can establish repurchase execution, operating margin and leverage against the August disclosures.

As of September 19, no company-confirmed results date within the next 30 days was established from the available event listing. The September 15 preferred-dividend date has elapsed; the earlier declaration alone does not verify payment. Company events

What Would Change Our Mind

Failure to retain the previously published advance would end the price thesis: a weekly close below $6.60 is the observable invalidation. The fundamental case would also fail if Q3 showed declining rebased revenue together with an adjusted OIBDA margin below the August 5 Q2 benchmark of 40%, or if the next disclosure showed no Q3 repurchases despite management's August 6 acceleration statement.

Conversely, a weekly close above the September 18 reference high of $8.85, accompanied by disclosed Q3 repurchases and a margin at least matching 40%, would establish the specified recovery case. A higher share price alone would not verify the operating thesis.

Correlation Notes

This remains a single-company situation: the September 18 evidence supplies no peer-return series or measured sector correlation. The August 6 disclosure of 4.6-times net leverage identifies a plausible sensitivity to financing conditions, but it does not quantify a relationship with credit spreads. A claim that a broader Emerging markets or telecom rally explains LILAK's advance would require evidence absent here.